Singer Jesy Nelson recently shared an emotional update regarding the complications she is experiencing in her pregnancy with twin babies. Former Little Mix singer Jesy, who is having twins with partner Zion Foster, announced that she has been diagnosed with pre-twin-to-twin transfusion syndrome (pre-TTTS). The condition, which is present in pregnancies involving twins with a shared placenta, has serious risks involved and needs intense medical supervision. As Nelson embarks on this difficult journey, her story enlightens us about a rare but dangerous condition many expectant parents may not know much about.

Twin-to-twin transfusion syndrome is a rare but dangerous condition that arises in monochorionic twin pregnancies, in which identical twins share a single placenta. The placenta supplies the developing babies with oxygen, nutrients, and blood flow, but in TTTS, there is an imbalance of blood vessels that interconnect the twins, and thus the vital resources are not evenly distributed. One twin, or the donor twin, shares excess blood with the other, referred to as the recipient twin. This leads to one baby becoming malnourished and possibly anemic, and the other in danger of heart problems due to too much blood.

Nelson described her diagnosis in a heartfelt Instagram video, explaining that she is currently in the pre-stage of TTTS and undergoing frequent monitoring. "I am being scanned twice a week, and each time, things have gotten a little worse," she shared, expressing her fears and hopes for the health of her babies.

Potential Risks of TTTS

If left untreated, TTTS can have devastating consequences. Medical research indicates that:

• 90% of the cases of untreated TTTS lead to loss of one or both twins.
• Despite treatment, only a 70% survival rate for both twins is assured.
• Severe forms can result in preterm labor, cardiac failure in the recipient twin, and organ failure in the donor twin.
• Complications in long-term survivors include neurological damage and developmental delay in surviving infants.

TTTS usually advances in stages, beginning with minimal changes in fluid levels and worsening as one twin continues to get an unequal share of blood. In extreme cases, fetal laser surgery, referred to as the Solomon technique, can be employed to divide the blood vessels and balance the twins.

Why Identical Twin Pregnancies Are More Complicated

Identical twins may develop differently, and their own unique form of placental sharing can have a dramatic effect on pregnancy risk. Jesy Nelson's twins are considered monochorionic diamniotic (mono/di), which means they share a placenta but have two amniotic sacs. This is the type of pregnancy in about 70% of identical twin pregnancies and carries an increased risk of complications like TTTS, umbilical cord entanglement, and growth restriction.

Conversely, dichorionic diamniotic (di/di) twins both have a separate placenta and amniotic sac, which greatly diminishes the threat of TTTS. Twin pregnancy type is normally identified by early ultrasound, with physicians being able to track future complications from inception.

Other Twin Pregnancy Health Risks

Twin pregnancies, even without the presence of TTTS, entail a variety of health risks to the mother as well as infants:

1. Premature Birth

Over 60% of twin pregnancies end in premature delivery, with birth usually taking place before 37 weeks. Premature infants can have immature organs and need neonatal intensive care (NICU) assistance to assist with breathing, feeding, and infection fighting.

2. Gestational Hypertension and Preeclampsia

Pregnant women with multiples are at increased risk of having high blood pressure during pregnancy. This, if left untreated, can result in preeclampsia, a serious complication of pregnancy that can result in damage to organs, preterm labor, and in some cases, maternal or fetal death.

3. Anemia

Pregnant women carrying multiples are twice as likely to experience anemia, a condition where the body does not produce enough healthy red blood cells. This can lead to fatigue, dizziness, and complications during delivery.

4. Birth Defects

According to John Hopkins Medicine, multiple birth babies are twice as likely to have congenital abnormalities compared to single births. These can include heart defects, neural tube defects, and gastrointestinal issues.

5. Amniotic Fluid Imbalances

When twins have to share a placenta, they are more likely to have polyhydramnios (excess amniotic fluid) or oligohydramnios (not enough amniotic fluid). Both result in distress to the babies during fetal development and can result in premature labor.

6. Postpartum Hemorrhage

Twins are at increased risk of excessive postpartum hemorrhage because their uterus is larger and there are greater blood supply needs.

Jesy Nelson's openness about her challenging experience is raising awareness for TTTS, a condition that few individuals—let alone expectant mothers and fathers—might be aware of. Through her tearful video, Nelson stressed the significance of knowing about twin pregnancies aside from the thrill of having multiples. "We had no idea that this type of thing occurs when you're having twins. We just desperately want to make people aware of this because there are so many people who aren't aware."

Her case reminds us of the intricacies involved in twin pregnancy and the significance of early identification and medical management. For mothers carrying twins, frequent ultrasounds and vigilance can become a life-and-death issue for early detection and better outcomes of both babies.

Through constant medical attention and care, she and her partner Zion Foster remain positive and get ready for their babies to be born. In other parents whose situations are no different, the story of Nelson highlights awareness, medical progress, and emotional encouragement in handling complicated pregnancies.

The expecting parents of twin siblings are advised to discuss TTTS screening and possible interventions with their physicians to give their babies the best chance.

On September 3, 1928, Scottish scientist Alexander Fleming returned to his laboratory after a holiday. He famously noticed the antibacterial effect of mold contaminating a Staphylococcus culture.

Fleming identified the mold as belonging to the Penicillium genus and found that it produced a substance capable of inhibiting bacterial growth, which he named penicillin.

However, Fleming’s discovery was only the beginning. Penicillin proved difficult to isolate, purify and mass-produce. During World War II, scientists Howard Florey and Ernst Chain built on Fleming’s work to develop large-scale production methods, converting penicillin into a life-saving medicine and ushering in the modern antibiotic era.

How Did Penicillin Resistance Develop?

As penicillin came into widespread medical use in the 1940s, resistance to the drug also emerged.

“Penicillin acts through a beta-lactam ring, which targets the bacteria, but then the organisms started producing an enzyme known as beta-lactamase,” Dr NK Ganguly, former Director General of the Indian Council of Medical Research (ICMR) told HealthandMe.

“This beta-lactamase broke the ring, so various derivative varieties of penicillins were synthesized,” he explained.

But as new penicillin derivatives were developed, bacteria also evolved or acquired mechanisms, including different beta-lactamases, that could break down these drugs.

As a result, penicillin became less effective against many bacteria. However, it remains effective against certain organisms and infections, including:

• Syphilis
• Group A beta-haemolytic Streptococcus
• Streptococcus pneumoniae (pneumococcus)

“Penicillin remains the gold standard for certain infections and indications, including neonatal sepsis, childhood pneumonia, rheumatic heart disease prophylaxis and resurging cases of syphilis,” Dr Ganguly said.

The Growing Threat Of Resistance

The story of penicillin resistance is an early example of a much broader problem the world is grappling with today: antimicrobial resistance (AMR), which threatens the effectiveness of modern healthcare.

Decades after antibiotics transformed medicine, the bacteria these drugs were designed to target have evolved significant resistance. This threat has been further compounded by the misuse and overuse of antibiotics across sectors.

According to the World Health Organization (WHO), approximately 1 in 6 laboratory-confirmed bacterial infections worldwide were resistant to antibiotic treatments in 2023.

Low- and middle-income countries bear the heaviest burden of infectious disease but face severe shortages of specialized antibiotics.

A global study covering 82 countries, led by the Murdoch Children’s Research Institute (MCRI), found that antibiotic resistance increased across every region between 2004 and 2022. As a result, critical treatments for routine childhood infections are becoming increasingly ineffective.

“The discovery of antibiotics is perhaps the most significant, life-changing breakthrough in the history of medicine,” Dr. Rajeev Jayadevan, Ex-President of IMA Cochin and Convener of the Research Cell, Kerala, told HealthandMe.

“However, bacteria possess natural evolutionary mechanisms to resist antibiotics as part of their survival machinery. Unfortunately, overuse in human healthcare, veterinary medicine and agriculture has allowed bacteria to continuously adapt and evade treatment,” he added.

Major Drivers Of Antimicrobial Resistance

Antimicrobial resistance is driven by a combination of clinical, agricultural, industrial and environmental factors:

1. Inappropriate syndromic and empirical prescribing
   • Viral infections
   • Unnecessary STD treatment
2. Self-medication and suboptimal adherence
3. Informal healthcare providers
4. Substandard and falsified medicines
5. Agricultural and veterinary misuse
   • Growth promoters in animal feed
   • Use of human-critical antibiotics in livestock
6. Industrial and environmental contamination
   • Manufacturing effluents
   • Fermentation and industrial waste
   • Effluents and sewage
7. Lack of public awareness

What Can Be Done?

So, are we running out of effective antibiotics? Not entirely, yet "the development of newer antibiotics has not kept pace with bacterial evolution" Dr Rajeev said.

Resistance is also making some infections increasingly difficult to treat. To counter, stronger national policies are needed the unnecessary antibiotic prescribing while ensuring that patients who genuinely need specialized antibiotics can access them.

Improving access will require coordinated action at both local and national levels. This includes:

• Ensuring quality-assured antibiotics are available and affordable in frontline healthcare settings
• Procuring the right antibiotics in adequate quantities
• Strengthening surveillance of antibiotic use
• Setting country-specific prescribing targets based on local disease burden and public health needs.

“Beyond discovering new drugs, the long-term solution lies in regulating antibiotic use globally—because antimicrobial resistance knows no boundaries. A resistant organism originating in one region can rapidly spread worldwide,” Dr Rajeev said.

A new experimental vaccine could offer protection against several forms of Streptococcus pneumoniae, showing promise for a future vaccine that will not have to fight each bacterial strain separately.

The bacterium, commonly called pneumococcus, can live in the nose and throat without causing any symptoms. But when the body's defenses are compromised and weakened, it can target other parts of the body and cause symptoms like pneumonia, meningitis, bloodstream infections and other serious diseases.

About The Study

One of the primary challenges of preventing these infections is that S. pneumoniae exists in more than 100 serotypes, or distinct versions of the bacterium. The current vaccines available to fight them only cover a selection of these types.

A new study published in Science Advances has found a different strategy. Instead of developing the vaccine around the sugar coating that differs between serotypes, researchers targeted proteins that is shared across pneumococcal strains.

Also read: H5N1 Detected In Captive Mink In US For First Time: Should You Be Concerned?

Current Pneumococcal Vaccines Have A Limitation

Existing pneumococcal vaccines work by instructing the immune system to recognise some components of the bacterium's outer shell.

Pneumococcal conjugate vaccines, or PCVs, combine these bacterial sugars with a carrier protein to produce a stronger immune response. Vaccines that target multiple serotypes have helped reduce invasive pneumococcal disease significantly.

But when vaccination reduces the prevalence of the serotypes that is included in a vaccine, other serotypes that are not covered can become more common. This phenomenon is known as serotype replacement.

Some of these replacement strains can also acquire antibiotic-resistance genes, which becomes another challenge.

This is why researchers have been exploring a vaccine that could provide protection across almost all pneumococcal serotypes, rather than having to continuously expand the list of strains covered.

Also read: Fall Vaccines 2026: US Doctors Issue COVID, Flu And RSV Jab Guidance

How Is The New Vaccine Developed?

Researchers opted for a reverse strategy to develop this universal vaccine. Instead of growing the bacterium and looking for useful components, researchers started with its genetic information.

They studied thousands of S. pneumoniae genomes to identify proteins that were conserved across different serotypes. The team looked for proteins that would:

• Be present on or accessible from the bacterial surface
• Be sufficiently different from human proteins
• Be capable of producing a strong immune response

From this analysis, researchers selected three proteins: zinc metalloprotease B (ZmpB), pneumococcal adherence and virulence factor A (PavA), and a YfhO-like protein.

These were combined with two immune-stimulating ingredients, CpG and chitosan, to create the experimental vaccine called ZPY-CpG-Ch.

Also read: 84% Cancer Patients Report Benefit From Ivermectin-Mebendazole: What The Study Found & Why More Trials Are Needed

Effects Of The Vaccine On Mice

Researchers tested the vaccine in both adult and mice to compare its performance with the 13-valent pneumococcal conjugate vaccine, PCV13.

In one experiment, vaccinated mice were exposed to serotype 1, a highly virulent strain of S. pneumoniae. The experimental vaccine produced 80% to 100% survival. The researchers also tested the vaccine against serotypes that are not covered by PCV13.

ZPY-CpG-Ch provided complete protection against serotypes 11A and 33F, while protection against serotype 8 was 50%.

The study found that the vaccine's protective effect was associated largely with a type of immune response that is be important in defense against pneumococcal infection.

The researchers also found that antibodies produced after vaccination could help kill pneumococci in laboratory experiments.

When these antibodies were transferred into unvaccinated mice, they provided protection against a lethal pneumococcal strain.

Despite the promising results, the researchers are not claiming that ZPY-CpG-Ch is ready for people.

The biggest limitation is that the work is still preclinical. The vaccine has been tested in mice but not in human clinical trials. The researchers also challenged the animals with only a small number of pneumococcal serotypes.

If the vaccine eventually proves to be safe and effective in humans, it could lead to wider protection against pneumococcal diseases.

A team of US scientists is beginning a human trial of a new form of proton therapy that could potentially deliver cancer-killing radiation in less than a second.

Known as FLASH proton therapy, the treatment requires fewer sessions — just five over about 10 days — and could potentially reduce the risk of treatment-related side effects.

FLASH Proton Therapy: The First Human Trial

The Phase I clinical trial at the Abramson Cancer Center of the University of Pennsylvania represents the first time the “conformal,” or precise 3D-targeting, version of the technique is being tested in human patients in the United States.

According to the University, the study will enroll 10 patients with recurrent head and neck cancer who have previously received radiation treatment and are not candidates for surgery.

Patients with recurrent head and neck cancer typically face a difficult prognosis. While radiation therapy can help treat the cancer, it can also cause side effects in areas involved in important functions such as eating, drinking and swallowing.

Patients in the trial will receive FLASH proton therapy five times in total, with each exposure lasting less than a second. They will complete all five sessions in less than two weeks.

Penn Medicine recently completed a FLASH proton therapy clinical trial in pet dogs with cancer. The canine study used the same technology for head and neck cancer that will be used in the human trial.

How Does FLASH Proton Therapy Work?

Proton therapy is an advanced form of radiation therapy that uses high-energy protons, or positively charged particles, to damage the DNA of cancer cells and destroy them.

Conventional radiation therapy is typically delivered in smaller doses, or fractions, over several weeks to target the tumour while limiting exposure to healthy tissue.

For patients with head and neck cancer, this typically means 25–35 radiation fractions, delivered once a day, five days a week, over five to six weeks.

Constantinos Koumenis, Professor of Radiation Oncology at Penn Medicine, explained that FLASH uses a larger dose and reduces the amount of time the patient is exposed to radiation.

The total effective radiation dose remains the same, but it is divided into fewer fractions, with each delivered in a large, lightning-fast dose.

What Is ConformalFLASH Proton Therapy?

The type of FLASH proton therapy being tested in this clinical trial is known as ConformalFLASH proton therapy.

The Penn clinical trial is designed to test the safety and feasibility of the approach. Researchers hope it could improve patients’ quality of life by reducing the time they spend in hospitals and travelling for treatment.

If successful, the approach could be expanded to other cancer types and studied in larger Phase II and Phase III clinical trials focused on treatment outcomes, the researchers said.